Liver Damage Warning Issued For Multaq

Washington, DC: Federal health officials have issued a warning to doctors and patients regarding the potential for liver damage associated with a recently launched drug for atrial fibrillation.

According to a report by the Associated Press the Food and Drug Administration said it has received reports of liver damage in patients taking Multaq (dronedarone) tablets, including two cases in which patients had to have their livers removed.

Multaq, approved by the FDA in July 2009, is marketed by Sanofi-Aventis SA. The drug is used to treat atrial flutter and atrail fibrillation, which are irregular heart rhythms that can result in stroke. Multaq carries a black box warning stating that it can cause severe adverse reactions and death in people with recent severe heart failure.

Recently, a study involving Multaq was halted because of concerns about cardiovascular events. The FDA is now examining preliminary results from the study.

Legal Help

If you or a loved one has suffered illness or an adverse health event resulting from the use of the product, please click the link below and your complaint will be sent to a lawyer who may evaluate your claim at no cost or obligation.
Last updated on Oct-27-11